文献速递前列腺癌

Johns Hopkins主动监测队列中PTEN状态评估

PTEN status assessment in the Johns Hopkins active surveillance cohort.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2018-10-02

该病例对照研究纳入Johns Hopkins主动监测队列中Gleason评分6分前列腺癌患者,评估活检组织PTEN免疫组化状态与后续分级重新分类的关联。结果显示PTEN缺失在对照组仅1.5%、病例组9%(p=0.062),差异未达统计学显著,但病例组中PTEN缺失更常见。

要点

  • GS6主动监测患者中PTEN缺失罕见,对照组仅1.5%。
  • 发生早期或极端分级重新分类者PTEN缺失比例更高(9% vs 1.5%)。
  • PTEN缺失与重新分类的关联未达统计学显著(p=0.062)。

核心结论

  • GS6前列腺癌主动监测患者中PTEN缺失罕见,但在发生早期或极端分级重新分类者中更常见。
  • PTEN状态与重新分类的关联未达统计学显著,需更大低危队列进一步验证。

研究设计与样本

  • 病例对照研究,纳入Johns Hopkins主动监测队列中有诊断活检组织可进行免疫组化染色的男性。
  • 病例67例(早期重新分类31例,极端重新分类36例),对照65例。
  • 对照为GS6且主动监测至少8年未发生活检重新分类者。

主要发现

  • 病例组诊断时中位年龄67岁,对照组65岁(p=0.024)。
  • 病例组符合极低危标准者64%,对照组79%(p=0.042)。
  • PTEN缺失在对照组65例中1例(1.5%),病例组67例中6例(9%)(p=0.062)。

关键数值与推荐

  • 早期重新分类定义为随访2年内活检分级至GS≥3+4=7。
  • 极端重新分类定义为随访中活检或根治性前列腺切除标本分级至GS≥4+3=7。
  • PTEN免疫组化采用经遗传学验证的方案。

临床怎么用

  • PTEN缺失在GS6主动监测人群中罕见,不宜单独作为排除主动监测的指标。
  • 对PTEN缺失患者可考虑更密切随访,但需更大样本验证其选择价值。

局限性

  • 样本量较小(病例67例、对照65例),PTEN缺失事件数少。
  • PTEN缺失与重新分类的关联未达统计学显著(p=0.062)。
  • 结论需在更大低危队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Up to half of men with Gleason score 6 (GS6) prostate cancers initially managed with active surveillance (AS) will eventually require definitive therapy, usually due to tumor grade reclassification during follow-up. We examined the association between PTEN status on biopsy and subsequent clinicopathologic outcomes in men with GS6 cancers who enrolled in AS. METHODS: We performed a case-control study of men enrolled in the Johns Hopkins AS cohort with diagnostic biopsy tissue available for immunohistochemical (IHC) staining. IHC was performed for PTEN using genetically validated protocols for all patients. Cases included men who underwent grade reclassification to GS ≥ 3 + 4 = 7 on biopsy within 2 years of follow-up (i.e., early reclassification) or reclassification to GS ≥ 4 + 3 = 7 on biopsy or radical prostatectomy during follow-up (i.e., extreme reclassification). Control patients were diagnosed with GS6 cancer and monitored on AS for at least 8 years without undergoing biopsy reclassification. RESULTS: Among 67 cases with adequate tissue, 31 men underwent early reclassification and 36 men underwent extreme reclassification. Cases were compared to 65 control patients with adequate tissue for assessment. On initial prostate biopsy, cases were older (median age 67 vs. 65, p = 0.024) and were less likely to meet very-low-risk criteria (64 vs 79%, p = 0.042) as compared to controls. Although not statistically significant, PTEN loss was observed in only 1 (1.5%) of 65 controls as compared to 6 (9%) of 67 cases (p = 0.062). CONCLUSIONS: PTEN loss was rare among men with GS6 prostate cancer enrolled in AS at Johns Hopkins. Despite this, PTEN loss was more frequent among men who underwent early or extreme reclassification to higher-grade cancer as compared to controls. Additional studies in larger low-risk cohorts may better elucidate a potential role for PTEN in selecting patients for AS.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Guedes LB, Morais CL, et al. PTEN status assessment in the Johns Hopkins active surveillance cohort. Prostate Cancer Prostatic Dis. 2018. PMID: 30279579. doi:10.1038/s41391-018-0093-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。